Javlor

Base Information

• Chemical Name: Javlor
• CAS No.: 162652-95-1
• Molecular Formula: C45H54F2N4O8
• Molecular Weight: 816.943
• NCI Thesaurus Code: C61564
• Nikkaji Number: J933.869A
• Wikidata: Q2195393
• Wikipedia: Vinflunine
• Mol file: 162652-95-1.mol

Synonyms:Javlor;vinflunine

Chemical Property of Javlor

Chemical Property:

• Refractive Index: 1.652
• PKA: 11.36±0.60(Predicted)
• PSA: 133.87000
• Density: 1.39 g/cm³
• LogP: 5.01950
• XLogP3: 4.4
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 13
• Rotatable Bond Count: 10
• Exact Mass: 816.39097102
• Heavy Atom Count: 59
• Complexity: 1720

Purity/Quality:

99% ^*data from raw suppliers

Vinflunine 98+% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
• Isomeric SMILES: CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)[C@H]([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C
• Recent ClinicalTrials: A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
• Recent EU Clinical Trials: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
• Recent NIPH Clinical Trials: None
• Description: Vinflunine (also referred to as PM391) is a semisynthetic analog of the natural vinca alkaloids vinblastine and vincristine that was approved by the European Medicines Agency (EMEA) in 2009 for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Vinflunine is synthesized from anhydrovinblastine in a superacid media (HF-SbF5) and in the presence of a chlorinated solvent like CHCl3 or CCl4.
• Clinical Use: Antineoplastic agent (vinca alkaloid): Treatment of advanced or metastatic bladder cancer
• Drug interactions: Potentially hazardous interactions with other drugs Antibacterials: possible increased risk of ventricular arrhythmias with delamanid; concentration possibly reduced by rifampicin - avoid. Antidepressants: concentration possibly reduced by St Johns wort - avoid. Antifungals: concentration increased by ketoconazole and possibly itraconazole (increased risk of neurotoxicity) - avoid. Antimalarials: avoid with piperaquine with artenimol. Antipsychotics: avoid with clozapine (increased risk of agranulocytosis). Antivirals: concentration possibly increased by ritonavir - avoid. Grapefruit juice: concentration of vinflunine increased - avoid.

Technology Process of Javlor

There total 1 articles about Javlor which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 35.0%

vinorelbine (71486-22-1) → vinflunine (162652-95-1)

Guidance literature:

With tetrachloromethane; hydrogen fluoride; antimony pentafluoride; at -40 ℃;

DOI:10.1021/ja971864w

Reference yield:

toluene-4-sulfonic acid (104-15-4) + vinflunine (162652-95-1) → vinflunine para-toluene sulfonate

Guidance literature:

In ethyl acetate; acetone;

Reference yield:

benzoic acid (65-85-0,8013-63-6) + vinflunine (162652-95-1) → vinflunine benzoate

Guidance literature:

In ethyl acetate;

upstream raw materials:

vinorelbine

Downstream raw materials:

vinflunine mandelate

vinflunine para-hydroxy-benzoate

Refernces